Elevated canine pancreatic lipase immunoreactivity concentration in dogs with inflammatory bowel disease is associated with a negative outcome.
To investigate whether elevated canine pancreatic lipase immunoreactivity (CPLI) concentrations in dogs with inflammatory bowel disease (IBD) is associated with a worse clinical outcome. Serum CPLI assays were performed on serum stored from cases diagnosed with IBD. Thirty-two dogs with CPLI results within the reference range were designated as the control group and 15 dogs had CPLI above the reference range. Clinical signs, age, serum lipase and amylase activities, serum albumin and cobalamin concentrations, abdominal ultrasound examination, histopathology on small intestinal biopsies, management of IBD and outcome were compared between the two groups. No significant differences were found in clinical activity score (P=0.54), number of antibiotic-responsive disease cases (P=0.480), number of steroid-responsive disease cases (P=0.491), serum amylase activity (P=0.058), serum cobalamin concentration (P=0.61), serum albumin concentration (P=0.052), abdominal ultrasound score (P=0.23) and histopathology scores for IBD (P=0.74) between the two groups. Dogs with increased CPLI concentration were significantly older and had a higher serum lipase activity than dogs with a CPLI concentration within the normal reference range (P=0.001, P=0.001, respectively). Moreover, dogs with increased CPLI concentration responded poorly to steroid treatment (P=0.01) and were significantly more likely to be euthanased at follow-up (P=0.02). CPLI should be measured in cases of canine IBD as elevated CPLI was associated with a worse outcome.